PD-L1 NEGATIVE

Clinical trials for PD-L1 NEGATIVE explained in plain language.

Never miss a new study

Get alerted when new PD-L1 NEGATIVE trials appear

Sign up with your email to follow new studies for PD-L1 NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

New hope for hard-to-treat breast cancer: targeted drug outperforms standard chemo in late-stage trial

Disease control Ongoing

This phase 3 study compares a targeted drug called sacituzumab govitecan against standard chemotherapy in about 623 people with advanced triple-negative breast cancer that does not express PD-L1 (a protein that makes immunotherapy work). Participants either have not received prio…

Matched conditions: PD-L1 NEGATIVE

Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control

Last updated Jun 27, 2026 12:04 UTC

PD-L1 NEGATIVE

Get alerted when new PD-L1 NEGATIVE trials appear

New hope for hard-to-treat breast cancer: targeted drug outperforms standard chemo in late-stage trial